MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2024 International Congress

    Parkinson’s Disease Clinical Subtypes Differ in Health-Related QOL

    E. Carr, T. Cash, C. Lessov-Schlaggar, H. Hwang, A. Eid, P. Kotzbauer, J. Perlmutter, M. Campbell (St. Louis, USA)

    Objective: To determine whether clinical subtypes of Parkinson disease (PD) differ in health-related quality of life (QOL). Background: Health-related QOL varies for individuals with PD.…
  • 2024 International Congress

    Health Care Utilization at the End-Of-Life in Parkinson´s Disease

    B. Leavy, E. åkesson, J. Lökk, T. Schultz, P. Strang, E. Franzén (Stockholm, Sweden)

    Objective: This study aims to increase knowledge concerning end of life health care utilization among an urban-dwelling Parkinson's disease (PD) cohort. More specifically we investigated frequency…
  • 2024 International Congress

    Nocturnal Use of Add-On Medications for Parkinson’s Disease: Post Hoc Analysis of the COSMOS Study

    T. Gurevich, S. O'Sullivan, J. Parra, M. O'Meara, J. Zamudio, A. Fasano (Tel Aviv-Yafo, Israel)

    Objective: To assess nighttime use of add-on medications for Parkinson’s disease (PD) in a post hoc analysis of the COSMOS (COmedication Study assessing Mono- and…
  • 2024 International Congress

    Subgroup Analyses of a Phase 3 Randomized Study of Levodopa/Carbidopa Infusion (ND0612) for Parkinson’s Patients

    W. Poewe, A. Espay, N. Lopes, J. Ferreira (Innsbruck, Austria)

    Objective: Evaluate efficacy and safety outcomes for different patient subgroups categorized according to their baseline characteristics from a Phase 3 study of ND0612. Background: Primary…
  • 2024 International Congress

    Efficacy and Safety of Foslevodopa/Foscarbidopa in People With Parkinson’s Disease With and Without Care Partner Support

    M. Soileau, J. Bronstein, L. Harmer, M. Shah, R. Gupta, L. Verhagen Metman (Georgetown, USA)

    Objective: To assess the efficacy and safety of foslevodopa/foscarbidopa (LDp/CDp) in people with Parkinson’s (PwP) with and without care partner support. Background: The progression of…
  • 2024 International Congress

    The HIIT-Home4Parkinson’s study

    C. Harpham, L. Connolly, H. Gunn, J. Marsden (Plymouth, United Kingdom)

    Objective: This study aims to evaluate the practicality and utility of a novel, co-created home-based high-intensity interval training (HIIT) programme for people with Parkinson’s (PwP).…
  • 2024 International Congress

    Parkinson’s Progression Markers Initiative (PPMI): Investigating Biomarker Driven PD Progression

    B. Mcmahon, A. Siderowf, T. Simuni, C. Tanner, B. Mollenhauer, C. Coffey, D. Galasko, K. Poston, L. Chahine, R. Dobkin, T. Foroud, K. Kieburtz, D. Weintraub, K. Merchant, M. Frasier, T. Sherer, S. Chowdury, E. Brown, R. Alcalay, A. Videnovic, K. Fabrizio, E. Flagg, C. Stanley, K. Marek (Baltimore, USA)

    Objective: PPMI is a longitudinal, observational study enrolling PD participants, individuals at risk for PD, and healthy controls (HCs). The study investigates clinical, imaging, genetic…
  • 2024 International Congress

    Comparison of olfactory testing and PSG for detection of alpha-synuclein pathology in patients with dream enactment behavior or REM sleep behavior disorder

    E. Brown, L. Chahine, A. Siderowf, C. Gochanour, C. Caspell-Garcia, M. Brumm, M. Marshall, C. Stanley, C. Soto, L. Concha, T. Sherer, T. Tanner, T. Simuni, K. Marek (San Francisco, USA)

    Objective: To compare the proportion of people with abnormal alpha-synuclein among groups with differing levels of certainty of REM sleep behavior disorder (RBD). Background: REM…
  • 2024 International Congress

    Pimavanserin Safety in Adult and Elderly Patients With Neuropsychiatric Symptoms Related to Neurodegenerative Disease: an Open-Label Extension Study

    W. Cubała, A. Berrio, K. Chi-Burris, G. Alva, L. Chrones, S. Pathak (Gdańsk, Poland)

    Objective: To assess the long-term safety and tolerability of pimavanserin in frail older adults and elderly patients with neuropsychiatric symptoms related to a neurodegenerative disease…
  • 2024 International Congress

    Identification of Allosteric GCase Correctors Using Revenir™ for the Treatment of GBA1-Parkinson’s Disease

    J. Dupaul-Chicoine, S. Lavallée, N. Azevedo Portilho, L. Gong, M. Fournel, I. Ghosh, MR. Goldsmith, M. Ebert, O. Rousseau, L. Fader, JF. Marquis, S. Hedge (Saint-Laurent, Canada)

    Objective: To identify novel non-inhibitory allosteric correctors of GCase using Congruence Therapeutic’s in silico proprietary drug discovery engine, Revenir™ Background: GBA1 encoding for glucocerebrosidase (GCase)…
  • « Previous Page
  • 1
  • …
  • 178
  • 179
  • 180
  • 181
  • 182
  • …
  • 436
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #24970 (not found)
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • An atypical and interesting feature of Parkinson´s disease
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley